Astellas Pharma Inc. - Total Cashflows From Financing Activities

Astellas Pharma Inc.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.

The item "Total-Cashflows-From-Financing-Activities" stands at -260.49 Billion Japanese Yens for the trailing twelve months (TTM) period ending 06/30/2025.

Astellas Pharma Inc.'s first quarter result of -11.04 Billion JPY for the item "Total Cashflows From Financing Activities" represents an increase of 87.84 percent compared to it's fourth quarter result of the company's last fiscal year.

Also, Astellas Pharma Inc.'s first quarter result of -11.04 Billion JPY for the item "Total Cashflows From Financing Activities" represents an increase of 7.36 percent compared to it's first quarter result of last year.

Looking again at the trailing twelve months series (TTM), Astellas Pharma Inc.'s first quarter result of -260.49 Billion JPY for the item "Total Cashflows From Financing Activities" represents an increase of 0.34 percent compared to it's fourth quarter result of the company's last fiscal year.


Regarding the One-Year-Change of the series, the current value constitutes an decrease of -697.59 Billion Japanese Yens compared to the value the year prior.
The 1 year change is -697.59 Billion Japanese Yens.
The 3 year change is -42.32 Billion Japanese Yens.
The 5 year change is -408.92 Billion Japanese Yens.
The 10 year change is -144.58 Billion Japanese Yens.

The Serie's long term average value is -83.16 Billion Japanese Yens. It's latest available value, on 06/30/2025, is -177.33 Billion Japanese Yens lower, compared to it's long term average value.
The Serie's change in Japanese Yens from it's minimum value, on 03/31/2025, to it's latest available value, on 06/30/2025, is +0.877 Billion.
The Serie's change in Japanese Yens from it's maximum value, on 03/31/2024, to it's latest available value, on 06/30/2025, is -874.55 Billion.